Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform","length":148,"tagName":"p"},{"type":"text","content":"ESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6, 2026. The appointment follows the planned departures of Suren Ajjarapu and Donald G. Fell, from the board.","length":447,"tagName":"p"},{"type":"text","content":""On behalf of our Board, I am delighted to welcome Phillip to the Aspire Biopharma Board. His leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen," said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board. "We are confident that his insights will help accelerate our strategy of reformulating established drugs with large markets and reinforce the Company's commitment to patients, customers, and shareholders."","length":516,"tagName":"p"},{"type":"text","content":"Phillip Balatsos is a senior financial markets executive and board director with over 25 years of experience across foreign exchange, emerging markets, institutional sales and trading, and public company governance. He has held leadership roles at global financial institutions including Barclays Capital, Credit Suisse, and XP Investments, and currently operates within an independent trading platform at Oscar Gruss & Son.","length":428,"tagName":"p"},{"type":"text","content":"In addition to his capital markets career, Mr. Balatsos brings entrepreneurial and operating experience, having founded and scaled a multi-location hospitality business and advised national restaurant groups on procurement, pricing, and operational efficiency. This background provides a pragmatic operator's perspective on margins, cost structures, and execution-particularly valuable in growth and turnaround environments.","length":428,"tagName":"p"},{"type":"text","content":"Mr. Balatsos currently serves on the Boards of Directors of Inspire Veterinary Partners, Inc., where he is a member of the ...

More updates from Aspire Biopharma Holdings, Inc.